Assessment of End-tidal Carbon Dioxide Levels in Respiratory Disease

Validity Assessment of End-tidal Carbon Dioxide Levels in Respiratory Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05188976

Enrollment

Registered

2022-01-12

Start date

2021-12-01

Completion date

2024-12-31

Last updated

2023-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Disease

Keywords

PetCO2

Brief summary

The investigators aim to evaluate the correlation between PetCO2, PaCO2, and PtcCO2 in patients with respiratory diseases. The investigators also evaluate the correlation between PetCO2, PaCO2, and PtcCO2 changes over time.

Detailed description

Partial pressure of carbon dioxide(PCO2) is mainly evaluated by partial pressure of arterial carbon dioxide (PaCO2), and is used as an index for prognosis and NPPV introduction in chronic respiratory failure. Arterial blood gas analysis for PaCO2 measurement is the most accurate test value, but it is invasive and frequent tests are difficult and cannot be performed at home. The transcutaneous PCO2 (PtcCO2) is a non-invasive measurement and its measured value is close to PaCO2, and it can be measured continuously, which is useful for monitoring patients with chronic respiratory failure. However, PtcCo2 has not been applied at home due to technical problems (necessity of calibration, periodic drift, etc.). The end-tidal pressure of expired CO2 (PetCO2) can be measured non-invasively, easily and continuously. PetCO2 is mainly used for patients undergoing mechanical ventilation, and its accuracy and stability have been evaluated. The investigators decided to investigate whether PetCO2 is useful for monitoring respiratory status in patients with respiratory disorder.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects with respiratory disorder. * Subjects who are clinically stable for the last 2 weeks

Exclusion criteria

* Subjects who required treatment with antibacterial agents or oral/intravenous steroids for pneumonia or exacerbation of respiratory disease in the last 2 weeks. * Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, and neurological disease.

Design outcomes

Primary

Measure	Time frame
Correlation between PetCO2, PaCO2, and PtcCO2	One to three months

Secondary

Measure	Time frame
Correlation of changes over time between PetCO2, PaCO2 , and PtcCO2	One to three months
Relationship between PetCO2 and respiratory symptoms evaluated by The COPD Assessment Test (CAT) and mMRC (modified British Medical Research Council)	One to three months

Countries

Japan

Contacts

Primary ContactYuichi Chihara, MD., PhD.

yc.r03107@gmail.com81-774-52-0065

Outcome results